Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GINKGO BIOWORKS HOLDINGS, INC.

(DNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Health Care Sits Out Broader Market Advance This Afternoon

10/06/2021 | 04:02pm EST


ę MT Newswires 2021
All news about GINKGO BIOWORKS HOLDINGS, INC.
11/30XpresSpa Teams Up With Ginkgo Bioworks to Include Detection of Omicron Variant in Airpo..
MT
11/30XpresSpa Group and Ginkgo Bioworks Collaboration with the Centers for Disease Control a..
AQ
11/29GINKGO BIOWORKS HOLDINGS, INC. SHARE : Robbins LLP Reminds Investors that Ginkgo Bioworks ..
BU
11/29Jefferies Starts Ginkgo Bioworks Holdings at Buy With $16 Price Target
MT
11/25SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ginkg..
PR
11/24GINKGO BIOWORKS HOLDINGS, INC. SHARE : Robbins LLP Informs Investors that Ginkgo Bioworks ..
BU
11/24GINKGO BIOWORKS HOLDINGS, INC. : Other Events (form 8-K)
AQ
11/24Ginkgo Bioworks Announces Participation in Upcoming Conferences
PR
11/17GINKGO ALERT : Bragar Eagel & Squire, P.C. is Investigating Ginkgo Bioworks Holdings, Inc...
BU
11/17Ginkgo Bioworks to Collaborate With mRNA Victoria on Vaccine Development, Biosecurity ..
MT
More news
Analyst Recommendations on GINKGO BIOWORKS HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2021 221 M - -
Net income 2021 -281 M - -
Net cash 2021 1 653 M - -
P/E ratio 2021 -103x
Yield 2021 -
Capitalization 16 934 M 16 934 M -
EV / Sales 2021 69,2x
EV / Sales 2022 62,4x
Nbr of Employees 495
Free-Float 73,3%
Chart GINKGO BIOWORKS HOLDINGS, INC.
Duration : Period :
Ginkgo Bioworks Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GINKGO BIOWORKS HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 11,39 $
Average target price 14,83 $
Spread / Average Target 30,2%
EPS Revisions
Managers and Directors
Jason Kelly Chief Executive Officer & Director
Reshma Shetty President, Chief Operating Officer & Director
Mark Dmytruk Chief Financial Officer
Arie S. Belldegrun Independent Director
Marijn E. Dekkers Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GINKGO BIOWORKS HOLDINGS, INC.0.00%16 934
MODERNA, INC.197.32%125 937
LONZA GROUP AG28.34%58 955
IQVIA HOLDINGS INC.44.70%49 527
SEAGEN INC.-9.64%28 937
CELLTRION, INC.-41.09%24 625